DVAX

Dynavax Technologies
DVAX

Latest price

Financial Snapshot

gainify

Market Data

Market Cap
$1.34B
EV
$876.83M
Shares Outstanding
124.67M
Beta
1.26

Wall Street View

Analyst Rating
OUTPERFORM
Analyst Target Price
$24.25
P/E 2025E
32.15x
P/Revenue 2025E
4.09x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Dynavax Technologies Corporation

gainify
DVAX

Dynavax Technologies Corporation

DVAX

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis ...

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Spencer, Ryan

Employees

405

IPO Date

2004-02-19

Headquarters

2100 Powell Street, Suite 720, EmeryVille, California, 94608, United States

gainify
mailcontactcontact
powered-by-sp

NEWSLETTER

COMPANY

© Copyright 2025, All Rights Reserved